Aspirin (Antiplatelet)
Brand names: Aspirin 75 mg, Anadin
Low-dose aspirin is an oral antiplatelet agent used for the secondary prevention of cardiovascular and cerebrovascular events and in established peripheral arterial disease.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It irreversibly inhibits platelet cyclo-oxygenase-1, blocking thromboxane A2 production and thereby platelet aggregation for the lifespan of the platelet.
Prescribing in practice
- It increases the risk of gastrointestinal and other bleeding, so it is avoided in active peptic ulceration and used cautiously with other antithrombotics, considering gastroprotection where appropriate.
- Avoid in known aspirin or NSAID hypersensitivity, including aspirin-exacerbated respiratory disease.
- It should not be given to children and young people because of the risk of Reye's syndrome.
Monitoring
Review bleeding symptoms, gastrointestinal tolerance and ongoing indication periodically.
Counselling the patient
- Take with or after food and report black stools, vomiting blood or unusual bleeding.
- Do not stop abruptly without advice if prescribed for heart or vascular protection.
Evidence & guidelines
Antithrombotic trial meta-analyses confirm low-dose aspirin reduces recurrent vascular events in patients with established cardiovascular disease.
Reference: NICE NG185; AHA guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- DAPT Score · Coronary Artery Disease
- ARC-HBR Criteria for High Bleeding Risk in PCI · Coronary Artery Disease
- PRECISE-DAPT Score for Bleeding on DAPT · Coronary Artery Disease
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- DAPT Decision Tool (Ticagrelor vs Clopidogrel) · Antiplatelet Therapy
- Peripheral Arterial Disease · NICE NG19 2012 / ESVS 2017
- Carotid Artery Disease · NICE CG68 / ESVS 2018
- Varicose Veins Management · NICE CG168 2013
- Venous Leg Ulcer Management · NICE NG204 2022
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185